Obstetrics and Gynecology Research and Education

Maternal-Fetal Medicine

The Division of Maternal-Fetal Medicine has an approved three-year fellowship training program. The purpose of the program is to provide an environment of scholarship that will enable the fellow to achieve a consultant's stature in maternal-fetal medicine.For additional information please visit the Graduate Medical Education Fellowship site for Maternal-Fetal Medicine.

Gynecologic Oncology

The Women's Cancer Program

The Cedars-Sinai Women’s Cancer Program, led by Beth Karlan, MD, at the Samuel Oschin Comprehensive Cancer Institute brings together Cedars-Sinai physicians and scientists to focus on how cancer impacts women. This includes both gender-specific cancers (such as breast and ovarian), and other cancers that may affect women differently than men (such as lung cancer).

The Women’s Cancer Program offers a wide variety of research studies and clinical trials.  The goals of the Women’s Cancer Program are:

  • To promote research between scientists and physicians to make sure that new laboratory discoveries can help women with cancer as quickly as possible.
  • To find new drugs and therapies that are personalized to the individual needs of women with cancer.
  • To identify health behaviors that can reduce the risk of cancer in women.
Clinical Therapeutic Trials

The Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute currently has many gynecologic clinical therapeutic trials open to accrual.  The clinical trials open in the Women’s Cancer Program are listed below or you can search for all trials available at Cedars-Sinai Medical Center by clicking HERE.

Ovarian/Peritoneal

     Primary Diagnosis

     IRB# 23694: GOG 0262

  • Eligibility:  Patients must have newly diagnosed stage III or IV ovarian, peritoneal, or fallopian tube cancer.  Patients may choose to enroll in this study prior to surgery and chemotherapy or after surgery.  Patients will choose one of two study treatments.
    • Paclitaxel (Taxol) every three weeks in combination with carboplatin given once every three weeks.  Patients may choose additional therapy with bevacizumab (Avastin).
    • Paclitaxel (Taxol) in combination with carboplatin given once per week in three-week cycles.  Patients may choose additional therapy with bevacizumab (Avastin).
  • Principal Investigator: BJ Rimel, MD

     IRB# 29958: GOG 3001

  • Eligibility:  Patients must have newly diagnosed stage III or IV ovarian, peritoneal, or fallopian tube cancer
  • Patients are treated with paclitaxel (Taxol) in combination with carboplatin every three weeks.  Patients will also receive the study drug (AMG 386) or placebo once per week in three-week cycles.
  • Principal Investigator: BJ Rimel, MD

     Recurrent Diagnosis

     IRB#30540: GOG 0186I

  • Eligibility:  Patients must have a diagnosis of recurrent or ongoing ovarian, peritoneal, or fallopian tube cancer.
  • Patients are treated with bevacizumab (Avastin) alone or bevacizumab (Avastin) and the study drug (fosbretabulin tromethamine – CA4P).
  • Principal Investigator: BJ Rimel, MD

     IRB#27395: Olaparib and Cediranib vs. Olaparib alone

  • Eligibility:  Patients must have a diagnosis of recurrent, high grade ovarian, peritoneal, or fallopian tube cancer and meet specific study criteria.
  • Patients are randomly assigned to take either olaparib and cediranib or olaparib alone.   The study drugs are in pill form and will need to be taken every day (no more than twice a day).
  • Principal Investigator: Andrew Li, MD

     Recurrence Prevention

     IRB# 29696: GOG 0225

  • Eligibility:  Patients who are in remission immediately following surgery and chemotherapy may enroll.
  • Patients are treated with either:
    • Lifestyle intervention including diet and exercise
    • General health education
  • Principal Investigator: BJ Rimel, MD

     IRB# 8439: GOG 0212

  • Eligibility:  Patients who are in remission immediately following surgery and chemotherapy may enroll.
  • Patients are treated with either:
    • Paclitaxel (Taxol) given once per month (every 28 days) for 12 months
    • Study drug (CT-2103) given once per month (every 28 days) for 12 months
    • No further therapy
  • Principal Investigator: BJ Rimel, MD


Endometrial/Uterine

     Primary Diagnosis

     IRB# 20566: GOG 0249

  • Eligibility:  Patients must have a diagnosis of stage IA-IIA endometrial carcinoma and meet specific study criteria.
  • Patients are treated with either:
    • Chemotherapy (paclitaxel and carboplatin) and vaginal radiation therapy
    • Pelvic radiation therapy
  • Principal Investigator: BJ Rimel, MD

     Recurrent Diagnosis

     IRB# 25908: TKI258

  • Eligibility:  Patients who have had one recurrence of uterine cancer and meet specific study criteria.
  • Patients are treated with oral TKI258 (pills) to be taken once per day, on a 5 days on/2 days off dosing schedule, to be repeated every 7 days
  • Principal Investigator: Andrew Li, MD

The Gilda Radner Hereditary Cancer Program

The Gilda Radner Hereditary Cancer Program, a program of Cedars-Sinai Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, is made up of several research studies for women at highest risk for breast and ovarian cancers - those with the BRCA1 or BRCA2 gene mutations.  Founded in 1991, the program brings together a team of physicians who specialize in gynecologic oncology, surgery, radiology, pathology and genetics.  Since the program started, over 1,600 women have participated in the program.  

Women’s Cancer Program Research Laboratories

The Women’s Cancer Program laboratories are studying cancer biology with a focus on developing new methods of early detection, prevention and treatments that will improve survival and quality of life for women.

Since 1988, the Women’s Cancer Program has maintained a tissue bank to contribute to research efforts at Cedars-Sinai Medical Center as well as research efforts worldwide.  The tissue bank currently contains over 100,000 specimens with follow up clinical and survival data that includes over 300 data variables.


The Women’s Cancer Program Registry

 The purpose of the WCP Registry is to create a large data registry focused on women’s cancers:

  • To help predict cancer risks
  • To identify participants for clinical trials and studies.  Studies may include clinical therapeutic trials for those with a personal history of cancer, screening studies for those without cancer, and other studies that follow individuals over time for data collection
  • To track outcomes of patients who are treated at participating centers and offices to find opportunities to improve care

Any woman over the age of 18 can participate in the WCP Registry.  The program enrolls women without a history of cancer as well as women with a personal history of cancer.  The Women’s Cancer Program is working with DocuSign to make it possible for patients to consent and complete the questionnaires online.  If you are interested in participating in the registry, please visit Research Cures Cancer.